Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

BMS ulcerative colitis drug suffers Phase II setback: regulatory roundup – Clinical Trials Arena,

The trial did not meet the primary endpoint of the proportion of patients who achieved clinical remission at 12 weeks. It also failed in achieving the …, The trial did not meet the primary endpoint of the proportion of patients who achieved clinical remission at 12 weeks. It also failed in achieving the …, Read More

Scroll to Top